AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca u.S. FDA site inspections conducted across manufacturing & R&D network (inspections)
Sustainability Data Annex — Product Quality & Patient Safety
Latest, FY2025
3
Period ended Dec 31, 2025
Change on a year earlier
-25.0%
4 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. FDA site inspections conducted across manufacturing & R&D network (inspections) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | -25.0% | Sustainability Data Annex 2025 ↗ |
| FY2024 | Dec 31, 2024 | 4 | -42.9% | Sustainability Data Annex 2025 ↗ |
| FY2023 | Dec 31, 2023 | 7 | +75.0% | Sustainability Data Annex 2025 ↗ |
| FY2022 | Dec 31, 2022 | 4 | – | Sustainability Data Annex 2024 ↗ |
Breakdown
What makes up u.s. fda site inspections conducted across manufacturing & r&d network (inspections)
- U.S. FDA inspection Form 483 observations received (observations)0 · FY2025
- Total U.S. FDA product recalls across classes (recalls)2 · FY2025
- Internal quality assurance audits of AstraZeneca manufacturing sites (audits)76 · FY2025
- External supplier & contract manufacturer quality assurance audits (audits)520 · FY2025
Cite this data
StockData. (2026). AstraZeneca U.S. FDA site inspections conducted across manufacturing & R&D network (inspections), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/esg_fda_inspections
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.